Advertisement

Hypoestrogenism and Estrogen Replacement Therapy in Women Suffering from Schizophrenia

  • Niels Bergemann
  • Christoph Mundt
  • Peter Parzer
  • Benno Runnebaum
  • Franz Resch

Keywords

Menstrual Cycle Estradiol Level Estrogen Replacement Therapy Premenstrual Symptom Conventional Antipsychotic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albus M, Maier W (1995) Lack of gender differences in age at onset in familial schizophrenia. Schizophr Res 18: 51–57PubMedCrossRefGoogle Scholar
  2. Angermeyer MC, Kühn L (1988) Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci 237: 351–364PubMedCrossRefGoogle Scholar
  3. Battey R (1876) Extirpation of the functionally active ovaries for the remedy of otherwise incurable diseases. Trans Am Gynecol Soc 1: 101–120Google Scholar
  4. Beck AT, Steer RA (1987) Beck depression inventory — Manual. San Antonio, The Psychological CorporationGoogle Scholar
  5. Behl C (2001) Estrogens — mystery drug for the brain. The neuroprotective activities of the female sex hormone. Springer, Wien New YorkGoogle Scholar
  6. Bergemann N, Jaggy S, Maier S, Kaiser D, Auler B, Parzer P, Resch F, Mundt Ch (2001) Estrogens effects on neuropsychological performance in schizophrenic women. Arch Women Ment Health 3(Suppl 2): 20–21Google Scholar
  7. Bergemann N, Mundt Ch, Resch F, Parzer P, Runnebaum B (1996) The hypoestrogenism hypothesis in female schizophrenia: preliminary hormone screening results. Eur Psychiatry 11(Suppl 4): 403Google Scholar
  8. Bergemann N, Mundt Ch, Parzer P, Jannakos I, Nagl I, Salbach B, Klinga K, Runnebaum B, Resch F (2004a) Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsy-chotics. Schizophr Res (in press)Google Scholar
  9. Bergemann N, Mundt Ch, Parzer P, Pakrasi M, Eckstein-Mannsperger U, Haisch S, Salbach B, Klinga K, Runnebaum B, Resch F (2004b) No additional effect of estrogen as an adjuvant therapy to antipsychotics for relapse prevention on the psychopathology and the course of illness in women with schizophrenia: results of a placebo-controlled double-blind study (submitted)Google Scholar
  10. Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt Ch, Resch F (2002) Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Women Ment Health 5: 119–126PubMedGoogle Scholar
  11. Bleuler E (1943) Die spätschizophrenen Krankheitsbilder. Neurologie 15: 259–290Google Scholar
  12. Brockington IF, Kelly A, Hall P, Deakin W (1988) Premenstrual relapse of puerperal psychosis. J Affect Disord 14: 287–292PubMedCrossRefGoogle Scholar
  13. Burger G (1984) Nerven-und Geisteskrankheiten als Indikationen für eine bilaterale Oophorektomie im späten 19. Jahrhundert. Dissertation, Med. Fakultät, Erlangen-NürnbergGoogle Scholar
  14. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 111: 11–20PubMedCrossRefGoogle Scholar
  15. Choi SH, Kang SB, Joe SH (2001). Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom Med 63: 822–829PubMedGoogle Scholar
  16. Clouston S (1906) Clinical lectures on mental disease. LondonGoogle Scholar
  17. Cyr M, Carlon F, Morissette M, DiPaolo T (2002) Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson’s disease. J Psychiatry Neurosci 27: 12–27PubMedGoogle Scholar
  18. DeLisi LE, Dauphinais ID, Hauser P (1989) Gender differences in the brain: are they relevant to the pathogenesis of schizophrenia? Compr Psychiatry 30: 197–208PubMedCrossRefGoogle Scholar
  19. Diczfalusy E, Lauritzen C (1961) Östrogene beim Menschen. Springer, BerlinGoogle Scholar
  20. DiPaolo T (1994) Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5: 27–42Google Scholar
  21. Fink G, Sumner BEH, McQueen JK, Wilson H, Rosie R (1998) Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiology 25: 764–775Google Scholar
  22. Fink G, Sumner BEH, Rosie R, Grace O, Quinn JP (1996) Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 16: 325–344PubMedCrossRefGoogle Scholar
  23. Forrest AD, Hay AJ (1971) Sex differences and the schizophrenic experience. Acta Psychiatr Scand 47: 137–149PubMedGoogle Scholar
  24. Garcia-Segura LM, Azcoitia I, DonCarlos LL (2001) Neuroprotection by estradiol. Progr Neurobiol 63: 29–60PubMedCrossRefGoogle Scholar
  25. Gattaz WF, Vogel P, Riecher-Rössler A, Soddu G (1994) Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry 36: 137–139PubMedCrossRefGoogle Scholar
  26. Georgi F, Fels E (1933) Follikelhormonbestimmungen im Harn schizophrener Frauen. Z Gesamte Neurol Psychiatrie 147: 746–756Google Scholar
  27. Glick J, Stewart D (1980) A new drug treatment for premenstrual exacerbation of schizophrenia. Compr Psychiatry 21: 281–287PubMedCrossRefGoogle Scholar
  28. Gordon JH, Borison RL, Diamond BI (1980) Modulation of dopamine receptor sensitivity by estrogen. Biol Psychiatry 15: 389–396PubMedGoogle Scholar
  29. Guy U (ed) (1976) ECDEU Assessmant manual for psychopharmacology, revised. DHEU Publication No. (ADM): 76–338. Rockville, National Institute of Mental HealthGoogle Scholar
  30. Häffner R (1912) Beziehungen zwischen Menstruation und Nerven-und Geistes-krankheiten auf Grund der Literatur und klinischer Studien. Z Gesamte Neurol Psychiatrie 9: 154–223Google Scholar
  31. Häfner H, an der Heiden W, Behrens S, Gattaz F, Hambrecht M, Löffler W, Maurer K, Munk-Jørgensen P, Nowotny B, Riecher-Rössler A, Stein A (1998) Causes and consequences of the gender differences in age at onset of schizophrenia. Schizophr Bull 24: 99–113PubMedGoogle Scholar
  32. Häfner H, Behrens S, De Vry J, Gattaz F (1991) Oestradiol enhences the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neuro-transmission. Evidence from an epidemiological study and from animal experiments. Eur ArchPsychiatr Clin Neurosci 241: 65–68Google Scholar
  33. Häfner H, Riecher-Rössler A, Maurer K, Fätkenheuer B, Löffler W (1992) First onset and early symptomatology of schizophrenia. A chapter of epidemiologicyl and neurobiological research into age and sex differences. Eur Arch Psychiatr Clin Neurosci 242: 109–118Google Scholar
  34. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K (1995) Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 37: 434–441PubMedGoogle Scholar
  35. Hallonquist JD, Seeman MV, Lang M, Rector NA (1993) Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 33: 207–209PubMedCrossRefGoogle Scholar
  36. Harris AH (1997) Menstrually related symptom changes in women with schizophrenia. Schizophr Res 27: 93–99PubMedGoogle Scholar
  37. Hautzinger M, Bailer M, Worall H, Keller F (1995) Beck-Depressions-Inventar (BDI). Testhandbuch, 2nd ed. Huber, BernGoogle Scholar
  38. Hegar A (1884) Castration als Mittel gegen nerv6se und psychische Leiden. Arch Gynäkologie 24: 318–323Google Scholar
  39. Hendrick V, Altshuler LL, Burt VK (1996) Course of psychiatric disorders across the menstrual cycle. Harvard Rev Psychiatry 4: 200–207Google Scholar
  40. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, Csernansky JG, Nordahl TE (2001) Association of estrogen levels with neuro-psychological performance in women with schizophrenia. Am J Psychiatry 158: 1134–1139PubMedCrossRefGoogle Scholar
  41. Huber TJ, Rollnik J, Wilhelms J, von zur Mühlen A, Emrich HM, Schneider U (2001) Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26: 27–35PubMedCrossRefGoogle Scholar
  42. Jolly Ph (1915) Menstruation und Psychose. Arch Psychiatrie Nervenkrankheiten 55: 637–686Google Scholar
  43. Kafka V (1935) Hormone bei Schizophrenie. Wien Med Wochenschr 85: 30–31Google Scholar
  44. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276PubMedGoogle Scholar
  45. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychoses. Br J Psychiatry 150: 662–673PubMedGoogle Scholar
  46. Klinga K (1994) Determination of hormones and hormone receptors. In: Runnebaum B, Rabe T (eds) Gynecological endocrinology and reproductive medicine, vol 1. Springer, Berlin Heidelberg New York, 45–54Google Scholar
  47. König C, Linzenmeier G (1913) Ueber die Bedeutung gynäkologischer Erkrankungen und den Wert ihrer Heilung bei Psychosen. Arch Psychiatrie Nervenkrankheiten 51: 1002–1054Google Scholar
  48. Könnecke R, Häfner H, Maurer K, Löffler W, an der Heiden W (2000) Main risk factors for schizophrenia: increased familial loading and pre-and peri-natal complications antagonize the protective effect of oestrogen in women. Schizophr Res 44: 81–93PubMedGoogle Scholar
  49. Kraepelin E (1909) Psychiatrie, Bd 1–4. Barth, LeipzigGoogle Scholar
  50. Krafft-Ebing R v (1878) Untersuchungen über das Irresein zur Zeit der Menstruation. Arch Psychiatrie Nervenkrankheiten 8: 65–107Google Scholar
  51. Krafft-Ebing R v (1903) Lehrbuch der Psychiatrie auf klinischer Grundlage für praktische Ärzte und Studierende, 7th ed. Ferd. Enke, StuttgartGoogle Scholar
  52. Kretschmer E (1921) Körperbau und Charakter. Springer, BerlinGoogle Scholar
  53. Kulkarni J, DeCastella A, Riedel A, Taffe J, Fitzgerald P, Burger H (2001) Estrogen — a potential new treatment in schizophrenia. Schizophr Res 48: 137–144PubMedCrossRefGoogle Scholar
  54. Kulkarni J, DeCastella A, Smith D, Taffe J, Keks N, Copolov D (1996) A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 20: 247–252PubMedCrossRefGoogle Scholar
  55. Lansbury J, Hughes J (1939) Estrin excretion in psychotic patients. Am J Psychiatry 95: 1119–1125Google Scholar
  56. Lee SJ, McEwen BS (2001) Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Toxicol 41: 569–591PubMedGoogle Scholar
  57. Leidenberger FA (1992) Klinische Endokrinologie für Frauenärzte. Berlin, SpringerGoogle Scholar
  58. Lewine RRJ (1981) Sex differences in schizophrenia. Psychol Bull 90: 432–444PubMedGoogle Scholar
  59. Lewine RRJ, Strauss JS, Gift TE (1981) Sex differences in age at first hospital admission for schizophrenia: a fact or artifact? Am J Psychiatry 138: 440–444PubMedGoogle Scholar
  60. Lindamer LA, Buse DC, Lohr JB, Jeste DV (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49: 47–51PubMedCrossRefGoogle Scholar
  61. Loranger AW (1984) Sex difference in age of onset of schizophrenia. Arch Gen Psychiatry 41: 157–161PubMedGoogle Scholar
  62. Mahe V, Dumaine A (2001) Oestrogen withdrawal associated psychoses. Acta Psychiatr Scand 104: 323–331PubMedCrossRefGoogle Scholar
  63. Mall G (1958) On the hormonal treatment of pre-and postmenstrual ovarian psychoses. In: Reiss M (ed) Psychoendocrinology. Grune & Stratton, Orlando, 96–103Google Scholar
  64. Mall G (1960) Diagnostik und Therapie ovarieller Psychosen. Zentralbl Gesamte Neurol Psychiatrie 155: 250Google Scholar
  65. Mayer CEL (1872) Menstruation im Zusammenhange mit psychischen Störungen. Beiträge zur Geburtshülfe und Gynäkologie 1: 111–135Google Scholar
  66. Mayer CEL (1869) Die Beziehungen der krankhaften Zustande in den Sexualorganen des Weibes zu Geistesstörungen. BerlinGoogle Scholar
  67. McEwen BS, Alvers SE (1999) Estrogen actions in the central nervous system. Endocrine Rev 20: 279–307CrossRefGoogle Scholar
  68. Melkersson KI, Hulting A-L, Rane AJ (2001) Dose requirement and prolactin elevation of anttipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51: 317–324PubMedCrossRefGoogle Scholar
  69. Morissette M, DiPaolo T (1993) Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 58: 16–22PubMedGoogle Scholar
  70. Nilsson P (1939) Der Prolan-und Follikulingehalt des Hams bei schizophrenen Frauen mit in der Genitalsphäre lokalisierten taktilen Halluzinationen. Upsala Läkareförenings Förhandlingar 44: 495–504Google Scholar
  71. Notman MT, Nadelson CC (2002). The hormone replacement therapy controversy. Arch Women Ment Health 5: 33–35.PubMedGoogle Scholar
  72. Nott PN (1982). Psychiatric illness following childbirth in Southampton: a case register study. Psychol Med 12: 557–561PubMedGoogle Scholar
  73. Oesterreicher W (1934) Die Ausscheidung des gonadotropen Hormons des Hypophy-senvorderlappens und des weiblichen Sexualhormons (Follikelhormon) bei Manien, Depressionen und Schizophrenien im geschlechtsreifen Alter. Wien Klin Wochenschr 46: 1385–1388Google Scholar
  74. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Reports 10: 799–812Google Scholar
  75. Rabe T, Runnebaum B (1997) Hormones. In: Runnebaum B, Rabe T (eds) Gynecological endocrinology and reproductive medicine, vol 1. Springer, Heidelberg Berlin New York, 1–43Google Scholar
  76. Reiss M (ed) (1958) Psychoendocrinology. Grune & Stratton, OrlandoGoogle Scholar
  77. Riecher-Rössler A (2003) Oestrogens and schizophrenia. Curr Opin Psychiatry 16: 187–192Google Scholar
  78. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R (1994) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20: 203–214PubMedGoogle Scholar
  79. Ross SM (1909): Menstruation in its relationships to insanity. J Mental Sci 55: 270–280Google Scholar
  80. Sacerdoti G, Carry E (1955) Funzionalità epatica e reattivita cutanea agli estrogeni in schizofreniche con iperestrogenismo. Rivista di Patologia Nervosa e Mentale 76: 781–790PubMedGoogle Scholar
  81. Saethre H (1933) Titrierung von Sexualhormonen bei Geisteskranken. Klin Wochenschr 12: 1409–1410Google Scholar
  82. Salokangas RR (1983) Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry 142: 145–151PubMedCrossRefGoogle Scholar
  83. Sartorius N, Jablensky A, Shapiro R (1978) Cross-cultural differences in the short-term prognosis of schizophrenic psychoses. Schizophr Bull 4: 102–113PubMedGoogle Scholar
  84. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, Day R (1986) Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol Med 16: 909–928PubMedCrossRefGoogle Scholar
  85. Schaefer A (1894) Einfluss der Psychose auf den Menstruationsvorgang. Allg Z Psychiatrie Psychisch-gerichtliche Medizin 50: 976–996Google Scholar
  86. Schneider HPG (2002) The view of the International Menopause Society on the Women’s Health Initiative. Climacteric 5: 211–216PubMedGoogle Scholar
  87. Schroeter R (1874) Die Menstruation in ihren Beziehungen zu den Psychosen. Z Psychiatrie 30: 551–572 (part 1); 31: 234–250 (part 2)Google Scholar
  88. Sears HA, Morter RA, Simonsen M, Williams C (1937) Blood estrin level in schizophrenia. Am J Psychiatry 93: 1293–1303Google Scholar
  89. Seeman MV (1997) Psychopathology in women and men: focus on female hormones. Am J Psychiatry 154: 1641–1647PubMedGoogle Scholar
  90. Seeman MV (1996) The role of estrogen in schizophrenia. J Psychiatry Neurosci 21: 123–127PubMedGoogle Scholar
  91. Seeman MV (1985) Sex and schizophrenia. Can J Psychiatry 30: 313–315PubMedGoogle Scholar
  92. Seeman MV (1983) Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 24: 125–128PubMedCrossRefGoogle Scholar
  93. Seeman MV (1982) Gender differences in schizophrenia. Can J Psychiatry 27: 107–112PubMedGoogle Scholar
  94. Smith S, Wheeler MJ, Murray R, O'Keane V (2002) The effects of antipsychotic induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22: 109–114PubMedCrossRefGoogle Scholar
  95. Swanson DW, Barron A, Floren A, Smith JA (1964) The use of norethynodrel in psychotic females. Am J Psychiatry 120: 1101–1103PubMedGoogle Scholar
  96. The North American Menopause Society (2003) Estrogen and progestogen use in peri-and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause 10: 497–506Google Scholar
  97. Tsuang MT, Dempsey GM, Rauscher FA (1976) A study of "atypical schizophrenia": comparison with schizophrenia and affective disorder by sex, age of admission, precipitant, outcome, and family history. Arch Gen Psychiatry 33: 1157–1160Google Scholar
  98. Tukey JW (1977) Exploratory data analysis. Reading Mass., Addison-WesleyGoogle Scholar
  99. Turgeon JL, McDonnel DP, Martin KA, Wise PM (2004) Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304: 1269–1273PubMedCrossRefGoogle Scholar
  100. Wells S (1886) Castration in mental and nervous diseases. A symposium by Sir T. Spencer Wells, Dr. Alfred Hegar and Robert Battey MD. Am J Med Sci 8: 455–471Google Scholar
  101. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. J Am Med Assoc 288: 321–333Google Scholar
  102. Writing Group of the International Menopause Society Executive Committee (2004) Guidelines for the hormone treatment of women in the menopause transition and beyond. Climacteric 7: 8–11Google Scholar

Copyright information

© Springer-Verlag/Wien 2005

Authors and Affiliations

  • Niels Bergemann
  • Christoph Mundt
  • Peter Parzer
  • Benno Runnebaum
  • Franz Resch

There are no affiliations available

Personalised recommendations